Insider Selling: Andrew K. Balo Unloads 10,000 Shares of DexCom Stock (DXCM)
DexCom (NASDAQ:DXCM) SVP Andrew K. Balo sold 10,000 shares of DexCom stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $38.19, for a total transaction of $381,900.00. Following the sale, the senior vice president now directly owns 159,099 shares in the company, valued at approximately $6,075,991. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, June 27th. They now have a $42.00 price target on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of DexCom from $38.00 to $40.00 in a research note on Tuesday, June 17th. They now have a “buy” rating on the stock. Finally, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $44.00 price target on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $39.60.
DexCom (NASDAQ:DXCM) traded up 1.45% on Tuesday, hitting $39.88. 793,290 shares of the company’s stock traded hands. DexCom has a one year low of $21.76 and a one year high of $49.83. The stock’s 50-day moving average is $38.26 and its 200-day moving average is $38.38. The company’s market cap is $2.988 billion.
DexCom (NASDAQ:DXCM) last released its earnings data on Thursday, May 1st. The company reported ($0.17) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.08) by $0.09. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $44.15 million. During the same quarter last year, the company posted ($0.16) earnings per share. DexCom’s revenue was up 59.1% compared to the same quarter last year. Analysts expect that DexCom will post $-0.33 EPS for the current fiscal year.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.